| HDAC6 is a microtubule-associated deacetylase C Hubbert, A Guardiola, R Shao, Y Kawaguchi, A Ito, A Nixon, M Yoshida, ... Nature 417 (6887), 455-458, 2002 | 2642 | 2002 |
| The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients T Osada, G Chong, R Tansik, T Hong, N Spector, R Kumar, HI Hurwitz, ... Cancer Immunology, Immunotherapy 57, 1115-1124, 2008 | 335 | 2008 |
| Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression CS Facemire, AB Nixon, R Griffiths, H Hurwitz, TM Coffman Hypertension 54 (3), 652-658, 2009 | 324 | 2009 |
| A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy B Theivanthiran, KS Evans, NC DeVito, M Plebanek, M Sturdivant, ... The Journal of clinical investigation 130 (5), 2570-2586, 2020 | 166 | 2020 |
| Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, ... Clinical Cancer Research 26 (16), 4268-4279, 2020 | 156 | 2020 |
| Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? AB Nixon, KA Schalper, I Jacobs, S Potluri, IM Wang, C Fleener Journal for immunotherapy of cancer 7, 1-14, 2019 | 134 | 2019 |
| Effect of pazopanib on tumor microenvironment and liposome delivery TD Tailor, G Hanna, PS Yarmolenko, MR Dreher, AS Betof, AB Nixon, ... Molecular cancer therapeutics 9 (6), 1798-1808, 2010 | 118 | 2010 |
| Phosphorylation and nuclear translocation of a regulator of G protein signaling (RGS10) PG Burgon, WL Lee, AB Nixon, EG Peralta, PJ Casey Journal of Biological Chemistry 276 (35), 32828-32834, 2001 | 114 | 2001 |
| Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment BA Hanks, A Holtzhausen, KS Evans, R Jamieson, P Gimpel, ... The Journal of clinical investigation 123 (9), 3925-3940, 2020 | 106 | 2020 |
| Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) AB Nixon, H Pang, MD Starr, PN Friedman, MM Bertagnolli, HL Kindler, ... Clinical Cancer Research 19 (24), 6957-6966, 2013 | 100 | 2013 |
| Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) SM Cushman, C Jiang, AJ Hatch, I Shterev, AB Sibley, D Niedzwiecki, ... Clinical Cancer Research 21 (5), 1078-1086, 2015 | 96 | 2015 |
| 5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A2 in Human Neutrophils (∗) J Wijkander, JT O'Flaherty, AB Nixon, RL Wykle Journal of Biological Chemistry 270 (44), 26543-26549, 1995 | 95 | 1995 |
| TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3 RA Hesler, JJ Huang, MD Starr, VM Treboschi, AG Bernanke, AB Nixon, ... Carcinogenesis 37 (11), 1041-1051, 2016 | 93 | 2016 |
| 5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway JT O'Flaherty, M Kuroki, AB Nixon, J Wijkander, E Yee, SL Lee, ... Journal of Biological Chemistry 271 (30), 17821-17828, 1996 | 91 | 1996 |
| 5-Oxo-eicosatetraenoate is a broadly active, eosinophil-selective stimulus for human granulocytes. JT O'Flaherty, M Kuroki, AB Nixon, J Wijkander, E Yee, SL Lee, ... Journal of immunology (Baltimore, Md.: 1950) 157 (1), 336-342, 1996 | 91 | 1996 |
| Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab Y Liu, MD Starr, A Bulusu, H Pang, NS Wong, W Honeycutt, A Amara, ... Cancer medicine 2 (2), 234-242, 2013 | 76 | 2013 |
| BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory … NB Mettu, E Twohy, FS Ou, TR Halfdanarson, HJ Lenz, R Breakstone, ... Annals of oncology 30, v203, 2019 | 69 | 2019 |
| Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators. JD Winkler, AN Fonteh, CM Sung, JD Heravi, AB Nixon, ... Journal of Pharmacology and Experimental Therapeutics 274 (3), 1338-1347, 1995 | 66 | 1995 |
| Effects of the combination of TRC105 and bevacizumab on endothelial cell biology Y Liu, H Tian, GC Blobe, CP Theuer, HI Hurwitz, AB Nixon Investigational new drugs 32, 851-859, 2014 | 65 | 2014 |
| The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival EM Thompson, ST Keir, T Venkatraman, C Lascola, KW Yeom, AB Nixon, ... Neuro-oncology 19 (9), 1217-1227, 2017 | 64 | 2017 |
